AMT is rolling out Glybera as a gene therapy for patients with this disease.

AMT is rolling out Glybera as a gene therapy for patients with this disease. In June of this year AMT announced new clinical data showing a one-period administration of its lead product Glybera outcomes in significant long-term health benefits for LPLD individuals. Long-term follow-up data from two clinical trials with complete LPLD patients display that Glybera therapy results in a significant and clinically important reduction in acute pancreatitis, the most debilitating complication of the disease. The data confirm that the treatment is well-tolerated and safe also. AMT intends to file Glybera for marketing acceptance with EMEA by the end of the year. Related StoriesCHOP experts delay symptoms, extend lifespan in animal style of Batten diseaseTumour DNA in the bloodstream can accurately monitor cancers in real timeEntirely new enzymatic process of DNA synthesisLPLchip predicated on the Progenika’s DNA-chip technology, will be utilized to rapidly diagnose sufferers with full and partial LPLD and will be important to effectively identify individuals that could reap the benefits of Glybera .‘We are learning more about how exactly autism affects men and women differently, along with the underlying etiological causes of these differences,’ said Alycia Halladay, PhD, chief science officer of the Autism Research Foundation. ‘This is a thrilling and promising possibility to leverage that understanding for deeper analysis into potential elements that could possess a significant effect on the lives of several people with autism. Right now, the limiting element is too little genetic data. The Autism Sisters Task shall help eliminate that barrier and move the science forward.’ The Autism Sisters Project will concentrate on three areas: Data on unaffected sisters will become collected from existing databases with rigorous behavioral phenotyping data on all family members, including unaffected siblings, beginning with samples in the Autism Sequencing Consortium; Funds will be provided to autism analysis sites in order that sequencing and phenotyping can be expanded to include an unaffected sister in families where samples from parents and the individual diagnosed with autism have already been collected New families with an associate who provides autism and a female sibling lacking any ASD diagnosis will become recruited to the Icahn School of Medicine at Mount Sinai to donate saliva samples and take part in a full screening.